Abstract
In 2010, a report on anti-GD2 immunotherapy in patients with high-risk neuroblastoma was published in the "Sanitary Technology Assessment Reports" collection.
The objective of the present report is to update the previous with the new evidence available on the efficacy and safety of anti-GD2 monoclonal antibodies in patients with high risk neuroblastoma.
Keywords
Cancer in children; Immunotherapy; Evidence-based medicine
Bibliographic citation
Solà I, Izquierdo F, Inmunoterapia anti-GD2 en pacientes con neuroblastoma de alto riesgo: actualización. Barcelona: Agència de Qualitat i Avaluació Sanitàries de Catalunya; 2014. (Informes de Evaluación de Tecnologías Sanitarias).
Audience
Professionals